A. Menarini Gmbh

A. Menarini Gmbh company information, Employees & Contact Information

Explore related pages

Related company profiles:

A. Menarini GmbH (Menarini) is the Swiss subsidiary of the MENARINI Group, Italy's largest pharmaceutical company in Florence. The family-owned pharmaceutical group ranks among the 20 largest pharmaceutical companies in Europe. With 17’000 employees worldwide, Menarini is present in more than 100 countries. Menarini’s R&D is based in Italy, Germany and Spain. Menarini sells original products in Primary and Specialty Care. Another focus is Consumer Health and Aesthetic Medicine. In Switzerland, we are located in Zurich Oerlikon, just a 7-minute walk away from the third most frequented train station in Switzerland. The young Swiss affiliate is composed of 46 people – about half in the Sales team. Our focus is Primary Care in diabetology, infectiology, allergology, gout arthritis, cardiovascular diseases, and also in the field of Specialty Care in aesthetic medicine.

Company Details

Employees
275
Founded
-
Address
Thurgauerstrasse 36/38, 9. Stock,switzerland
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Zürich-Oerlikon, Zürich
Looking for a particular A. Menarini Gmbh employee's phone or email?

A. Menarini Gmbh Questions

News

UPC grants PI to Abbott in dispute with Sinocare and Menarini - JUVE Patent

UPC grants PI to Abbott in dispute with Sinocare and Menarini JUVE Patent

Matthijs Van Meerveld: New Journey Brings New Responsibilities at Menarini Stemline in New York City - Oncodaily

Matthijs Van Meerveld: New Journey Brings New Responsibilities at Menarini Stemline in New York City Oncodaily

Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-famil - PR Newswire

Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-famil PR Newswire

Menarini and ERBC collaborate - European Biotechnology Magazine

Menarini and ERBC collaborate European Biotechnology Magazine

Tempus AI, Inc. (TEM) and Menarini Group Leverage AI to Advance Breast Cancer Care - Yahoo Finance

Tempus AI, Inc. (TEM) and Menarini Group Leverage AI to Advance Breast Cancer Care Yahoo Finance

Menarini, Insilico Medicine deepen AI partnership with potential $550M deal - Mobi Health News

Menarini, Insilico Medicine deepen AI partnership with potential $550M deal Mobi Health News

Insilico wins second Menarini deal with oncology candidate - BioWorld MedTech

Insilico wins second Menarini deal with oncology candidate BioWorld MedTech

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology - GlobeNewswire

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology GlobeNewswire

Menarini and Insilico announce $550M deal for new cancer therapy - drugdiscoverytrends.com

Menarini and Insilico announce $550M deal for new cancer therapy drugdiscoverytrends.com

Insilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M deal - Fierce Biotech

Insilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M deal Fierce Biotech

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer - Business Wire

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer Business Wire

Menarini is late to go early with Orserdu | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Menarini is late to go early with Orserdu | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bold moves, bolder vision: A CEO’s path for innovative pharma - McKinsey & Company

Bold moves, bolder vision: A CEO’s path for innovative pharma McKinsey & Company

Menarini, a bridge with US against the deadliest diseases - Italpress

Menarini, a bridge with US against the deadliest diseases Italpress

Menarini selects Kuehne+Nagel to deliver consumer healthcare across Türkiye - Kuehne+Nagel

Menarini selects Kuehne+Nagel to deliver consumer healthcare across Türkiye Kuehne+Nagel

Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer - Fierce Pharma

Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer Fierce Pharma

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg - PR Newswire

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg PR Newswire

BOTTICELLI, THE INQUIETUDE AND THE BEAUTY - Menarini presents in Florence its latest art monograph, dedicated to the symbol of the Italian Renaissance - PR Newswire

BOTTICELLI, THE INQUIETUDE AND THE BEAUTY - Menarini presents in Florence its latest art monograph, dedicated to the symbol of the Italian Renaissance PR Newswire

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets - PR Newswire

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets PR Newswire

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe - PR Newswire

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe PR Newswire

Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine - Contract Pharma

Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine Contract Pharma

Menarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidate - Fierce Biotech

Menarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidate Fierce Biotech

Menarini Group and Radius Health Announce Global License - GlobeNewswire

Menarini Group and Radius Health Announce Global License GlobeNewswire

Menarini becomes exclusive distributor for INVOKANA® (canagliflozin) and VOKANAMET® (fixed-dose combination of canagliflozin and metformin) in the UK - The Diabetes Times

Menarini becomes exclusive distributor for INVOKANA® (canagliflozin) and VOKANAMET® (fixed-dose combination of canagliflozin and metformin) in the UK The Diabetes Times

Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer - Business Wire

Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer Business Wire

Industria Italiana Autobus becomes (back) Menarini. New owner Seri Industrial announces name change - Sustainable Bus

Industria Italiana Autobus becomes (back) Menarini. New owner Seri Industrial announces name change Sustainable Bus

NICE recommends Menarini’s Nexpovio combination to treat multiple myeloma - PMLiVE

NICE recommends Menarini’s Nexpovio combination to treat multiple myeloma PMLiVE

Italy’s Menarini Group to acquire Stemline Therapeutics for $677M - MedCity News

Italy’s Menarini Group to acquire Stemline Therapeutics for $677M MedCity News

Chugai licenses out early-stage cancer candidate to Menarini - Fierce Biotech

Chugai licenses out early-stage cancer candidate to Menarini Fierce Biotech

Geely takes a 25% stake in Menarinibus (former Industria Italiana Autobus) - Sustainable Bus

Geely takes a 25% stake in Menarinibus (former Industria Italiana Autobus) Sustainable Bus

Italy’s Menarini Group Snaps Up Stemline Therapeutics for $667 Million - BioSpace

Italy’s Menarini Group Snaps Up Stemline Therapeutics for $667 Million BioSpace

Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe - PR Newswire

Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe PR Newswire

Photos: A.Menarini 25th Anniversary Meeting - Irish Medical Times

Photos: A.Menarini 25th Anniversary Meeting Irish Medical Times

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer - Indian Pharma Post

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer Indian Pharma Post

A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System - PR Newswire UK

A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System PR Newswire UK

Menarini Group Heirs Set To Inherit $10.4B, But The Tax Man Is After Them - Forbes

Menarini Group Heirs Set To Inherit $10.4B, But The Tax Man Is After Them Forbes

Menarini Asia-Pacific reinvents pharmaceuticals in the region - South China Morning Post

Menarini Asia-Pacific reinvents pharmaceuticals in the region South China Morning Post

Menarini India Strengthens Its Dermatology Portfolio, Enters into an Exclusive Partnership Agreement with Pierre Fabre Laboratories to Market Global Brands Eau Thermale Avene and Ducray in India - Business Wire India

Menarini India Strengthens Its Dermatology Portfolio, Enters into an Exclusive Partnership Agreement with Pierre Fabre Laboratories to Market Global Brands Eau Thermale Avene and Ducray in India Business Wire India

Menarini strengthens its presence in aesthetic dermatology in India - Business Standard

Menarini strengthens its presence in aesthetic dermatology in India Business Standard

Insulet Corporation vs Menarini Diagnostics and EOFlow - Solicitors Journal

Insulet Corporation vs Menarini Diagnostics and EOFlow Solicitors Journal

Menarini India introduces Definisse double-needle threads - BioSpectrum India

Menarini India introduces Definisse double-needle threads BioSpectrum India

Lupin acquires five brands from Menarini - Express Pharma

Lupin acquires five brands from Menarini Express Pharma

A. Menarini Pharmaceuticals announces resumption of Frovex 2.5mg tablets supplies - Irish Medical Times

A. Menarini Pharmaceuticals announces resumption of Frovex 2.5mg tablets supplies Irish Medical Times

Lupin acquires five brands from Menarini - Moneycontrol

Lupin acquires five brands from Menarini Moneycontrol

Menarini and partners roll out free cognitive assessment tests - Citizens Journal

Menarini and partners roll out free cognitive assessment tests Citizens Journal

How Menarini Asia Pacific achieves organisational excellence, harnesses agile go-to market approaches - Singapore Business Review

How Menarini Asia Pacific achieves organisational excellence, harnesses agile go-to market approaches Singapore Business Review

Processo Menarini. I fratelli Aleotti assolti dall'accusa di riciclaggio - Fedaiisf

Processo Menarini. I fratelli Aleotti assolti dall'accusa di riciclaggio Fedaiisf

Italian pharma giant Menarini eyes India brands - Business Standard

Italian pharma giant Menarini eyes India brands Business Standard

Phl affiliate of Italy’s Menarini launched - Philstar.com

Phl affiliate of Italy’s Menarini launched Philstar.com

Check out the hologram sticker...Korea Menarini Guides the Distributio - SportsChosun

Check out the hologram sticker...Korea Menarini Guides the Distributio SportsChosun

Top A. Menarini Gmbh Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant